| Recruitment status | Open public recruiting |
| Unique ID issued by UMIN | UMIN000031951 |
| Receipt No. | R000036340 |
| Official scientific title of the study | Prospective study on identification of effectiveness, safety and effect predictors of benralizumab for bronchial asthma |
| Date of disclosure of the study information | 2018/03/28 |
| Last modified on | 2018/04/18 (Ver. 4) |
| Basic information | ||
| Official scientific title of the study | Prospective study on identification of effectiveness, safety and effect predictors of benralizumab for bronchial asthma | |
| Title of the study (Brief title) | J-BEST | |
| Region |
|
|
| Condition | ||||
| Condition | bronchial asthma | |||
| Classification by specialty |
|
|||
| Classification by malignancy | Others | |||
| Genomic information | NO | |||
| Objectives | |
| Narrative objectives1 | Identification of effectiveness, safety and effect predictors of benralizumab for bronchial asthma |
| Basic objectives2 | Safety,Efficacy |
| Basic objectives -Others | |
| Trial characteristics_1 | Exploratory |
| Trial characteristics_2 | |
| Developmental phase | |
| Assessment | |
| Primary outcomes | Relationship between effect predictors before administration and improvement of symptoms after 12 weeks |
| Key secondary outcomes | 1. Improvement of questionnaire on quality of life (AQLQ), asthma control test (ACT) score, exacerbation frequency, respiratory function one second amount (FEV 1), divided into two groups at the median of various effect predicting factors before administration
2. The relationship between the variation of various indices and the improvement of AQLQ score, ACT score, exacerbation frequency, FEV 1 3. The time course of various effect predictors 4. Asthma control (the ratio of the number of strokes up to the 12th week, the ratio of unscheduled outpatient visits to the 12th week (including emergency outpatient visits)) 5. Effect of drug reduction scale 6. The incidence of adverse events of Grade 1 or higher during treatment 7. When continuing treatment with benralizumab after 12 weeks, adverse events from the onset of treatment of benralizumab to one year |
| Base | |
| Study type | Observational |
| Study design | |
| Basic design | |
| Randomization | |
| Randomization unit | |
| Blinding | |
| Control | |
| Stratification | |
| Dynamic allocation | |
| Institution consideration | |
| Blocking | |
| Concealment | |
| Intervention | |
| No. of arms | |
| Purpose of intervention | |
| Type of intervention | |
| Interventions/Control_1 | |
| Interventions/Control_2 | |
| Interventions/Control_3 | |
| Interventions/Control_4 | |
| Interventions/Control_5 | |
| Interventions/Control_6 | |
| Interventions/Control_7 | |
| Interventions/Control_8 | |
| Interventions/Control_9 | |
| Interventions/Control_10 | |
| Eligibility | ||||
| Age-lower limit |
|
|||
| Age-upper limit |
|
|||
| Gender | Male and Female | |||
| Key inclusion criteria | 1) Patients diagnosed with bronchial asthma according to general allergy guideline 2016
2) Patients with bronchial asthma using high-dose inhaled corticosteroids and long-acting beta 2 agonists 3) Patients who obtain written consent regarding the participation of this study |
|||
| Key exclusion criteria | 1) Patients who have previously received benralizumab
2) Patients with severe complications such as heart disease, liver disease or kidney failure 3) Patients judged unsuitable as subjects by doctor's judgment |
|||
| Target sample size | 25 | |||
| Research contact person | |
| Name of lead principal investigator | Takehiro Izumo |
| Organization | Japanese Red Cross Medical Center |
| Division name | Respiratory Medicine |
| Address | 4-1-22, Hiroo, Shibuya-ku, Tokyo, Japan |
| TEL | 03-3400-1311 |
| drtake1118@gmail.com | |
| Public contact | |
| Name of contact person | Takehiro Izumo |
| Organization | Japanese Red Cross Medical Center |
| Division name | Respiratory Medicine |
| Address | 4-1-22, Hiroo, Shibuya-ku, Tokyo, Japan |
| TEL | 03-3400-1311 |
| Homepage URL | |
| drtake1118@gmail.com | |
| Sponsor | |
| Institute | Japanese Red Cross Medical Center |
| Institute | |
| Department | |
| Funding Source | |
| Organization | Japanese Red Cross Medical Center |
| Organization | |
| Division | |
| Category of Funding Organization | Self funding |
| Nationality of Funding Organization | |
| Other related organizations | |
| Co-sponsor | |
| Name of secondary funder(s) | |
| Secondary IDs | |
| Secondary IDs | NO |
| Study ID_1 | |
| Org. issuing International ID_1 | |
| Study ID_2 | |
| Org. issuing International ID_2 | |
| IND to MHLW | |
| Institutions | |
| Institutions | |
| Other administrative information | |||||||
| Date of disclosure of the study information |
|
||||||
| Progress | |||||||
| Recruitment status | Open public recruiting | ||||||
| Date of protocol fixation |
|
||||||
| Anticipated trial start date |
|
||||||
| Last follow-up date | |||||||
| Date of closure to data entry | |||||||
| Date trial data considered complete | |||||||
| Date analysis concluded | |||||||
| Related information | |
| URL releasing protocol | |
| Publication of results | Unpublished |
| URL releasing results | |
| Results | |
| Other related information | Prospective study |
| Management information | |||||||
| Registered date |
|
||||||
| Last modified on |
|
||||||
| Link to view the page | |
| URL(English) | https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000036340 |